TWI924678B - Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法 - Google Patents

Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法

Info

Publication number
TWI924678B
TWI924678B TW110122923A TW110122923A TWI924678B TW I924678 B TWI924678 B TW I924678B TW 110122923 A TW110122923 A TW 110122923A TW 110122923 A TW110122923 A TW 110122923A TW I924678 B TWI924678 B TW I924678B
Authority
TW
Taiwan
Prior art keywords
mmol
trans
cyclohexyl
dimethyl
phenyl
Prior art date
Application number
TW110122923A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216680A (zh
Inventor
馬修 D 亞歷山德
馬修 D 寇瑞亞
迪帕克 杜維
維吉娜 海勒 莎倫 古蘭特
約書亞 漢森
羅伊 Ｌ 三世 海瑞斯
伊凡 Ｊ 霍爾
德華 黃
克里斯多弗 麥恩
史蒂芬 諾利斯
克尼特斯基 維羅尼克 普朗特維恩
約翰 Ｊ 薩彼恩茲
莉達 德蘭尼
布蘭頓 Ｗ 懷特菲爾德
Original Assignee
美商西建公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西建公司 filed Critical 美商西建公司
Publication of TW202216680A publication Critical patent/TW202216680A/zh
Application granted granted Critical
Publication of TWI924678B publication Critical patent/TWI924678B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
TW110122923A 2020-06-24 2021-06-23 Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法 TWI924678B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043555P 2020-06-24 2020-06-24
US63/043,555 2020-06-24

Publications (2)

Publication Number Publication Date
TW202216680A TW202216680A (zh) 2022-05-01
TWI924678B true TWI924678B (zh) 2026-05-11

Family

ID=79032408

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110122923A TWI924678B (zh) 2020-06-24 2021-06-23 Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法

Country Status (16)

Country Link
US (3) US11634407B2 (enExample)
EP (1) EP4171566A4 (enExample)
JP (2) JP7781792B2 (enExample)
CN (2) CN120441548A (enExample)
AR (1) AR122723A1 (enExample)
AU (1) AU2021296833A1 (enExample)
BR (1) BR112022025933A2 (enExample)
CA (1) CA3182325A1 (enExample)
CL (1) CL2022003719A1 (enExample)
CO (1) CO2022018653A2 (enExample)
IL (1) IL299256A (enExample)
MX (1) MX2022015757A (enExample)
PE (1) PE20231746A1 (enExample)
SA (1) SA522441857B1 (enExample)
TW (1) TWI924678B (enExample)
WO (1) WO2021262810A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith
KR20240026939A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483A (zh) * 2006-03-09 2007-09-12 陈德桂 调节雄激素受体活性的乙内酰脲衍生物的组成及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2020051260A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
BR112021011968A2 (pt) 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) * 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483A (zh) * 2006-03-09 2007-09-12 陈德桂 调节雄激素受体活性的乙内酰脲衍生物的组成及其应用

Also Published As

Publication number Publication date
US11634407B2 (en) 2023-04-25
KR20230027066A (ko) 2023-02-27
CO2022018653A2 (es) 2023-03-27
MX2022015757A (es) 2023-01-19
JP2023533203A (ja) 2023-08-02
JP2026035702A (ja) 2026-03-04
CA3182325A1 (en) 2021-12-30
SA522441857B1 (ar) 2024-07-21
BR112022025933A2 (pt) 2023-01-10
EP4171566A1 (en) 2023-05-03
WO2021262810A1 (en) 2021-12-30
TW202216680A (zh) 2022-05-01
PE20231746A1 (es) 2023-11-06
US20210403454A1 (en) 2021-12-30
CL2022003719A1 (es) 2023-05-12
US20250188056A1 (en) 2025-06-12
JP7781792B2 (ja) 2025-12-08
EP4171566A4 (en) 2024-07-24
CN120441548A (zh) 2025-08-08
AR122723A1 (es) 2022-09-28
CN115835866B (zh) 2025-05-02
US20230242509A1 (en) 2023-08-03
CN115835866A (zh) 2023-03-21
AU2021296833A1 (en) 2023-01-19
IL299256A (en) 2023-02-01
US12103920B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
JP7724911B2 (ja) 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法
US12103920B2 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CN115955979B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
KR102864064B1 (ko) 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
CN115968293B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
JP2019535658A (ja) 医薬化合物
CN117561249A (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
EA047871B1 (ru) Соединения, связывающие цереблон, композиции на их основе и способы лечения с их применением
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
JP2024526182A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法